Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azathioprine + febuxostat
- Development stage
- Preclinical
- Lead developer
- Teijin Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of two medications: azathioprine, an immunosuppressive agent, and febuxostat, a xanthine oxidase inhibitor. This combination is generally contraindicated due to a significant drug interaction. Febuxostat inhibits xanthine oxidase, which normally metabolizes azathioprine's active metabolite (6-mercaptopurine) into inactive products. This inhibition causes increased plasma concentrations of azathioprine or mercaptopurine, potentially leading to toxicity and myelosuppression.
02
Targets
XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on azathioprine + febuxostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azathioprine + febuxostat.